Experienced pharmaceutical and management leader with 20+ years in generics and NCE drug product development. Familiar with R&D and filing of innovative drugs as well as domestic generic drugs;
Dr.Feng worked as CEO of Hangzhou Qing Yue, the vice president of Chongqing Liangjiang, the CEO of Shanghai Apeloa, the vice director of R&D of Roche (China), and the Scientist of Merck (Singapore);
Successfully led in 5 NCE drug products (oncology, viral, diabetes) approved for domestic and international clinics. Advance the approval of several generic drugs (Apixaban, Sorafenib, Tenofovir Alafenamide, etc.)
PhD in Organic Chemistry from the National University of Singapore.
PhD in Organic Chemistry, National University of Singapore; MS, Dalian University of Technology; Postdoc,The Hong Kong Polytechnic University.

Nearly 30 years of experience in new drug R&D, dedicated to research on API manufacturing R&D and GMP production of various types of new drugs, with extensive experience in new drug R&D CMC management;
Dr. Zhang worked as Senior Technical Director at Theravance and Senior scientist at Abbott Laboratories (Abbott);
Led in more than 20 new drug development in the areas of COPD, asthma, antibiotics, anti-liver cancer, anti-hepatitis C, chronic inflammatory bowel disease, heart failure, IBD, and chronic prostate hyperplasia, etc.; of which 5 new drugs have been marketed, including Breo Ellipta, Yupelri, Televancin and Cethromycin; more than 10 joined projects are in clinical phase 1 to 3;
PhD in Medicinal Chemistry, University of Wisconsin-Milwaukee; BS and MS, Shanghai #1 Medical School.

Experienced with over 30 years of expertise in drug product development, specializing in diverse dosage forms including oral, injectable, inhalation, transmucosal, and transdermal delivery systems.
Proven track record of leadership in advancing pharmaceutical pipelines at Anesta, Theravance Biopharma, Achaogen, and CoTherix.
Led the development of four FDA-approved products including Synera (lidocaine/ tetracaine patch), Actiq (oral transmucosal fentanyl citrate), Zemdri (plazomicin injection), and Yupelri (revefenacin inhalant), as well as dozens of oral and inhaled drugs in clinical development;
PhD in Pharmaceutical Science, University of Wisconsin-Madison; BS, Fudan University.